ANI Pharmaceuticals, Inc.

NasdaqGM:ANIP Stock Report

Market Cap: US$1.5b

ANI Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:ANIP Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
05 Mar 26SellUS$302,240Stephen CareyIndividual4,000US$75.56
03 Mar 26SellUS$445,380Patrick WalshIndividual6,000US$74.23
03 Mar 26SellUS$157,590Ori GutwergIndividual2,060US$76.50
05 Dec 25SellUS$146,070Renee TannenbaumIndividual1,800US$81.15
13 Nov 25SellUS$750,904Patrick WalshIndividual8,643US$86.88
13 Nov 25SellUS$8,272Chad GassertIndividual94US$88.00
12 Nov 25SellUS$1,304,163Chad GassertIndividual14,642US$89.07
03 Sep 25SellUS$692,302Antonio PeraIndividual7,292US$94.94
25 Aug 25SellUS$229,087Matthew LeonardIndividual2,528US$90.62
22 Aug 25SellUS$160,609Krista DavisIndividual1,763US$91.10
21 Aug 25SellUS$9,036,008Esjay LlcCompany100,000US$90.44
20 Aug 25SellUS$486,426Antonio PeraIndividual5,421US$89.73
18 Aug 25SellUS$611,635Matthew LeonardIndividual6,937US$88.17
18 Aug 25SellUS$1,920,370Jeanne ThomaIndividual21,540US$89.76
15 Aug 25SellUS$801,450Patrick WalshIndividual9,000US$89.05
15 Aug 25SellUS$1,739,400Chad GassertIndividual20,000US$86.97
15 Aug 25SellUS$8,824,533Esjay LlcCompany100,000US$89.48
12 Aug 25SellUS$1,661,972Thomas HaugheyIndividual19,341US$85.93
12 Aug 25SellUS$508,191Ori GutwergIndividual5,873US$86.53
12 Aug 25SellUS$4,894,573Nikhil LalwaniIndividual56,960US$85.93
12 Aug 25SellUS$426,407Thomas RowlandIndividual4,975US$85.71
15 May 25SellUS$52,922Ori GutwergIndividual881US$60.07
14 May 25SellUS$241,800Christopher MutzIndividual4,000US$60.45

Insider Trading Volume

Insider Buying: ANIP insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of ANIP?
Owner TypeNumber of SharesOwnership Percentage
State or Government4,0270.0165%
Private Companies436,9201.79%
Individual Insiders1,439,7025.91%
Institutions22,492,52292.3%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 65.78% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
12.8%
BlackRock, Inc.
2,661,594US$192.9m4.42%no data
6.25%
The Vanguard Group, Inc.
1,305,068US$94.6m2.16%no data
4.86%
MVP Capital Partners
1,014,381US$73.5m0%100.0%
3.48%
State Street Global Advisors, Inc.
727,204US$52.7m2.18%no data
2.83%
Global Alpha Capital Management Ltd.
590,135US$42.8m-6.42%1.27%
2.58%
Millennium Management LLC
539,665US$39.1m727%0.03%
2.34%
Dimensional Fund Advisors LP
487,667US$35.4m-3.51%no data
2.33%
Soleus Capital Management, L.P.
486,243US$35.2m42.9%1.51%
2.31%
Tang Capital Management, LLC
481,437US$34.9m51.6%1.73%
2.29%
Deep Track Capital, LP
477,684US$34.6m6.15%0.81%
2.29%
Geode Capital Management, LLC
477,272US$34.6m4.2%no data
2.27%
Arrowstreet Capital, Limited Partnership
473,207US$34.3m31.4%0.02%
2.07%
Esjay Llc
431,920US$31.3m0%no data
1.94%
Nikhil Lalwani
404,889US$29.4m-1.54%no data
1.74%
Ranger Investment Management, L.P.
362,378US$26.3m33.5%1.89%
1.73%
The Goldman Sachs Group, Inc.
360,589US$26.1m25%0.01%
1.52%
William Blair Investment Management, LLC
316,693US$23.0m-9.17%0.03%
1.51%
Renaissance Technologies LLC
314,402US$22.8m15.2%0.04%
1.43%
Nomura Investment Management Business Trust
299,278US$21.7m2.8%0.03%
1.31%
Teachers Insurance and Annuity Association-College Retirement Equities Fund
272,602US$19.8m-13.9%no data
1.29%
Columbia Management Investment Advisers, LLC
269,903US$19.6m-7.52%no data
1.21%
D. E. Shaw & Co., L.P.
253,536US$18.4m19%0.02%
1.21%
Charles Schwab Investment Management, Inc.
251,634US$18.2m6.78%no data
1.15%
Aberdeen Group Plc
240,792US$17.5m-10.7%0.01%
1.12%
Chad Gassert
233,406US$16.9m0.56%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/13 06:51
End of Day Share Price 2026/03/13 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ANI Pharmaceuticals, Inc. is covered by 16 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Glen SantangeloBarclays
Dewey SteadmanCanaccord Genuity
Timothy ChiangCapital One Securities, Inc.